文献速递消化道肿瘤放疗

利用非靶向代谢组学预测局部进展期直肠癌新辅助放化疗的病理反应

Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer.
PubMed 文献 · Radiother Oncol · 2018-07-02

该研究采用基于液相色谱-质谱联用的非靶向代谢组学分析106例局部进展期直肠癌患者新辅助放化疗前的血清样本,筛选出57个差异代谢峰和15个代谢生物标志物。57个代谢峰组合在偏最小二乘法、随机森林和支持向量机模型中的AUC分别为0.88、0.81和0.84,提示代谢组学具有预测新辅助放化疗反应的潜力。

要点

  • 共检测到4810个代谢峰,其中57个代谢峰在放化疗敏感与抵抗患者间显著失调。
  • 57个代谢峰组合在偏最小二乘法、随机森林和支持向量机模型中的AUC分别为0.88、0.81和0.84。
  • 鉴定出15个代谢生物标志物用于构建逻辑回归模型并探索失调代谢通路。

核心结论

  • 鉴定出一组代谢物有助于预测局部进展期直肠癌患者对新辅助放化疗的肿瘤反应,有望用于制定个体化治疗策略。

研究设计与样本

  • 采用基于液相色谱-质谱联用的非靶向代谢组学分析106例接受新辅助放化疗的局部进展期直肠癌患者血清样本。
  • 样本采集于复旦大学附属肿瘤医院,时间为2014年7月至2016年1月。
  • 根据肿瘤退缩分级,采用偏最小二乘法和Wilcoxon秩和检验识别放化疗敏感与抵抗患者间的判别代谢物。
  • 该试验注册于ClinicalTrials.gov,注册号为NCT03149978。

主要发现

  • 共检测到4810个代谢峰,其中57个代谢峰显著失调。
  • 在包含放化疗敏感患者(n=56)和放化疗抵抗患者(n=49)的数据集中,使用偏最小二乘法以57个代谢峰区分患者。
  • 57个代谢峰组合在偏最小二乘法、随机森林和支持向量机预测模型中的AUC分别为0.88、0.81和0.84。
  • 鉴定出15个代谢生物标志物,用于构建逻辑回归模型并探索失调代谢通路。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The present study aimed to identify a panel of potential metabolite biomarkers to predict tumor response to neoadjuvant chemo-radiation therapy (NCRT) in locally advanced rectal cancer (LARC). EXPERIMENTAL DESIGN: Liquid chromatography-mass spectrometry (LC-MS)-based untargeted metabolomics was used to profile human serum samples (n = 106) from LARC patients treated with NCRT. The samples were collected from Fudan University Shanghai Cancer Center (FUSCC) from July 2014 to January 2016. Statistical methods, such as partial least squares (PLS) and Wilcoxon rank-sum test, were used to identify discriminative metabolites between NCRT-sensitive and NCRT-resistant patients according to their tumor regression grade (TRG). This trial is registered with Clinical Trials.gov, number NCT03149978. RESULTS: A panel of metabolites was selected as potential predictive biomarkers of pathological response to NCRT. A total of 4810 metabolic peaks were detected, and 57 significantly dysregulated peaks were identified. These 57 metabolic peaks were used to differentiate patients using PLS in a dataset containing NCRT-sensitive (n = 56) and NCRT-resistant (n = 49) patients. The combination of 57 metabolic peaks had AUC values of 0.88, 0.81 and 0.84 in the prediction models using PLS, random forest, and support vector machine, respectively, suggesting that metabolomics has the potential ability to predict responses to NCRT. Furthermore, 15 metabolite biomarkers were identified and used to construct a logistic regression model and explore dysregulated metabolic pathways using untargeted metabolic profiling and data mining approaches. CONCLUSIONS: A panel of metabolites has been identified to facilitate the prediction of tumor response to NCRT in LARC, which is promising for the generation of personalized treatment strategies for LARC patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Jia H, Shen X, Guan Y, et al. Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer. Radiother Oncol. 2018. PMID: 30041962. doi:10.1016/j.radonc.2018.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。